Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoOVSV Vaccine in Patients With Ovarian Cancer After Surgery
NCT07724106Phase 1Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Sep 2026
- Primary completion
- May 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in ovarian cancer, sponsored by West China Hospital of Sichuan University. Primary endpoint: Safety assessment at 18 months. Started Sep 2026; status: recruiting.
02
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT07724106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07724106.